AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy

Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking. We investigated whether Zinc-alpha 2 glycoprotein (AZGP1) expression in the diagnostic biopsies of men with hormone-naïve prostate cancer (PCa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mads Dochedahl Winther, Gitte Kristensen, Hein Vincent Stroomberg, Kasper Drimer Berg, Birgitte Grønkær Toft, James D. Brooks, Klaus Brasso, Martin Andreas Røder
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2020-07-01
coleção:	Diagnostics
Assuntos:	prostate cancer AZGP1 biomarker androgen deprivation therapy
Acesso em linha:	https://www.mdpi.com/2075-4418/10/8/520
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!